OncoCyte company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.


Founded Year



Unattributed - V | IPO

Total Raised


Market Cap


About OncoCyte

OncoCyte (NYSEAMERICAN: OCX) is focused on the discovery, development, and commercialization of non-invasive, liquid biopsy diagnostics for the early detection of cancer. OncoCyte is developing diagnostic tests for lung cancer, breast cancer, and bladder cancer.

OncoCyte Headquarter Location

15 Cushing

Irvine, California, 92618,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing OncoCyte

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

OncoCyte is included in 1 Expert Collection, including Cancer.



3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

OncoCyte Patents

OncoCyte has filed 4 patents.

patents chart

Application Date

Grant Date


Related Topics



Experimental cancer drugs, Monoclonal antibodies, Oncology, Medical imaging, Monoclonal antibodies for tumors


Application Date


Grant Date


Related Topics

Experimental cancer drugs, Monoclonal antibodies, Oncology, Medical imaging, Monoclonal antibodies for tumors



Latest OncoCyte News

People in the News at Oncocyte, OraSure, Illumina Ventures, More

Aug 12, 2022

Save for later Oncocyte has appointed Gisela Paulsen as president and Anish John as CFO. Paulsen has been COO of the company since October and will also continue in that position, Oncocyte said in a Form 8-K filed with the US Securities and Exchange Commission. Prior to joining the firm, she was GM of precision oncology at Exact Sciences, and before that she held various management positions at Roche and its subsidiary Genentech, including SVP and global head of product development and clinical operations at both firms from January 2018 to April 2020. John was previously SVP of finance at Oncocyte and had been its interim CFO since June. Prior to that, he was VP of operations and finance for the transplant business unit at Oncocyte. He was also senior director of financial planning and analysis for Foundation Medicine, now part of Roche. Before that, John was at PerkinElmer where he held various management roles. OraSure Technologies: Kenneth McGrath, Scott Gleason, Mara Aspinall OraSure Technologies has appointed Kenneth McGrath as CFO, replacing Scott Gleason, who had served as interim CFO and will continue leading investor relations and corporate communications. McGrath was most recently with Quest Diagnostics as its VP of finance. Prior to that, he held various leadership positions in finance with Johnson & Johnson. OraSure also announced that Michael Celano, chairman of the board, and Ronny Lancaster and Eamonn Hobbs have resigned from the board, reducing its size to seven from 10. Effective Nov. 8, Mara Aspinall will become chairman of OraSure's board. She is managing director of Health Catalysts Group and BlueStone Venture Partners. She previously was chief executive of Ventana Medical Systems, now Roche Tissue Diagnostics. She was also chief executive of Genzyme Genetics. Additionally, Aspinall cofounded the Biomedical Diagnostics Master Degree program at Arizona State University. Illumina Ventures: Arnaud Autret, William Byrne, Ronan Byrne, and Ivan Coulter Illumina Ventures has added Arnaud Autret as principal and head of European operations, William Byrne as an associate, and Ronan Byrne and Ivan Coulter as venture advisors. Autret comes to the firm from M Ventures, the venture capital arm of Merck KGaA. He holds a doctorate in immunology from the Pasteur Institute. William Byrne holds a doctorate in tumor immunology from University College Cork and an MBA from INSEAD. Ronan Byrne is CEO and cofounder of Pharma Latch. He holds an MBA from University College Dublin. Coulter is founder and managing director of Eden BioPharma. He holds a doctorate in cancer research from University College Dublin and an MBA from Cornell University. For additional recent items on executive appointments, promotions, and departures in the omics and molecular diagnostics space, please see the People in the News page on our website.

OncoCyte Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

OncoCyte Rank

  • When was OncoCyte founded?

    OncoCyte was founded in 2009.

  • Where is OncoCyte's headquarters?

    OncoCyte's headquarters is located at 15 Cushing, Irvine.

  • What is OncoCyte's latest funding round?

    OncoCyte's latest funding round is Unattributed - V.

  • How much did OncoCyte raise?

    OncoCyte raised a total of $28.95M.

  • Who are the investors of OncoCyte?

    Investors of OncoCyte include Lineage Cell Therapeutics and University of Utah.

  • Who are OncoCyte's competitors?

    Competitors of OncoCyte include Cofactor Genomics and 1 more.

You May Also Like

Cofactor Genomics Logo
Cofactor Genomics

Cofactor Genomics bridges the precision medicine gap by building diagnostic tools to match the right patient to the right treatment at the right time. Cofactor provides Predictive Immune Modeling, which leverages RNA data and machine learning to combine biological signals, creating multidimensional biomarkers for new diagnostics to improve patient outcomes.

Cadex Genomics Logo
Cadex Genomics

Cadex Genomics develops molecular diagnostic tests to guide cancer treatment using liquid-based technology to provide personalized insight into the therapy response. By combining proven approaches to measuring DNA with technology to improve accuracy and sensitivity Cadex Genomics provides unique insight into therapy response using simple blood draws.

Guardant Health Logo
Guardant Health

Guardant Health has developed genomic cancer testing from a single blood draw, helping oncologists learn information about patients while avoiding the costs and risks of tissue biopsies. The genomic test helps match advanced-cancer patients to approved targeted therapies as well as drugs in clinical trials.

NanoString Technologies

NanoString Technologies is a provider of life science tools for translational research and developer of molecular diagnostics. The company's nCounter Analysis System delivers highly multiplexed, direct profiling of individual molecules in a single reaction without amplification. The nCounter Analysis System offers a cost-effective way to profile gene transcripts, copy number variations, or miRNAs simultaneously with high sensitivity and precision. The company's technology enables a variety of basic research and translational medicine applications, including biomarker discovery and validation. NanoString is also developing the technology for use in molecular diagnostics.In June 2013, NanoString Technologies went public with a valuation of $145 million.

Foundation Medicine Logo
Foundation Medicine

Foundation Medicine is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient's unique cancer. The company's initial clinical assay, FoundationOne, is a fully informative genomic profile to identify a patient's individual molecular alterations and match them with relevant targeted therapies and clinical trials. Foundation Medicine's molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer.FoundationOne is a fully informative genomic profile that complements traditional cancer decision tools and often expands treatment options by matching each patient with targeted therapies that may be relevant to the molecular changes in their tumor. Using next-generation sequencing, FoundationOne interrogates all genes somatically altered in human cancers that are validated targets for therapy or unambiguous drivers of oncogenesis based on current knowledge. It reveals all classes of genomic alterations including base substitutions, insertions, deletions, copy number alterations and select rearrangements. Each patient's genomic profile is reported to the physician matched with targeted therapies and clinical trials that may be relevant based on the molecular blueprint of their tumor. Results are supported by the latest scientific and medical evidence. FoundationOne has been optimized to fit easily into the clinical workflow of a practicing oncologist. It is available for all solid tumors and clinical grade results can be obtained from as little as 50ng of DNA obtained from formalin-fixed, paraffin-embedded tumor tissue samples. FoundationOne is a laboratory-developed test performed at Foundation Medicine's CLIA-certified facility and is currently available for all solid tumor types.On June 18th, 2018, Foundation Medicine was acquired by Roche Holdings at a valuation of $5.3B.

Exact Sciences Logo
Exact Sciences

Exact Sciences (NASDAQ: EXAS) is an applied genomics company with a mission to contribute to the eradication of common cancers by applying advances in the field of genomics to facilitate the early detection of diseases. The company was founded in 1995 and is based in Madison, Wisconsin.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.